Immunisation with a T-cell dependent antigen has been promoted as a reliable and sensitive tool for assessing the influence of putative immunotoxic exposures or agents on immune function. Keyhole limpet haemocyanin (KLH) is a very large, copper-containing protein molecule derived from the haemolymph of the inedible mollusc, Megathura crenulata. KLH is a highly immunogenic T-cell dependent antigen that is used increasingly in immunotoxicological studies, particularly in those involving animals. This report systematically reviews the human clinical studies that have used trans-cutaneous KLH immunisation for assessment of the influence of various physiological and disease states and exposures on immune function over the last twenty years (1994 -2013). These studies varied in their immunisation protocols, formulation of KLH, dose, site and route of administration and immunoassay platforms developed to assess KLH-specific responses. KLH immunisation has been well tolerated with only mild to moderate adverse effects reported. Though very promising as a model antigen candidate in immunotoxicology research, more work on standardising immunisation and immunoassay protocols is required.
Introduction
The effect of extrinsic (e.g. environmental exposure) or intrinsic (e.g. psychological distress) factors on the human immune system can be effectively assessed by quantifying the antigen-specific response to immunisation with a T-cell dependent antigen, although care needs to be taken with the choice of antigen (1,2). Keyhole limpet haemocyanin (KLH) is an immunogenic protein antigen that is xenogeneic to the mammalian immune system. It is used primarily in animal immunotoxicological studies but has a number of applications in the human context including as a vaccine conjugate peptide and in immunotherapy. However, practical aspects regarding the utility of KLH as a diagnostic antigen in human immunotoxicology studies have not previously been reviewed in detail.
This paper describes the ideal attributes of a vaccine candidate for human immunotoxicology studies and the structure and immunostimulatory properties of KLH. We then present a systematic review of the use of KLH immunisation via trans-cutaneous routes in human immunotoxicological studies over the period 1994-2013, including its safety profile and the relevant immunoassay platforms required to assess the immune response to immunisation.
Use of T-cell dependent antigens in immunotoxicological studies
Quantification of the primary antibody response to immunisation with a T-cell dependent (TD) antigen (e.g. sheep red blood cells, ovalbumin, KLH, tetanus toxoid, hepatitis B surface antigen) is a sensitive method for assessing immunocompetence (3) (4) (5) (6) . The immune response to immunisation with a TD antigen is commonly referred to as a T-cell dependent antibody response (TDAR) (7) .
Immunisation with a TD antigen permits assessment of the complex primary immune response that involves antigen presentation, priming and collaboration of T and B lymphocytes, antibody production and cytokine-dependent antibody class switching (6) .
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In animal immunotoxicological research, assessment of a TDAR using sheep erythrocytes or KLH has become the functional immune assay of choice (8) (9) (10) . For human immunotoxicology studies, opportunistic monitoring of the responses to routine childhood vaccinations (e.g. tetanus, diphtheria, pertussis) has been advocated (11, 12) .
What makes an ideal immunisation antigen candidate for immunotoxicology studies?
The properties of an ideal TD antigen for immunisation have been previously described (11, 13, 14) and include the following: A similar and potent immune response was seen in participants immunised with the HMW-KLH and sub-unit KLH with adjuvant, but not in those immunised with sub-unit KLH alone. It was postulated that the lack of response was not due to a lack of important immunogenic epitopes in sub-unit-KLH but, instead, was due to an adjuvant property of HMW KLH that was successfully substituted by use of the mineral oil adjuvant.
A measureable, robust antigen-specific immune response can be generated following administration of KLH via a number of routes -intra-dermal (35,37,40), sub-cutaneous (33,36,43-45), intramuscular (28,30-32,38,42) and inhalational (39). Studies that administered KLH intra-muscularly used the deltoid muscle. Site of sub-cutaneous administration was documented over the deltoid (44) or "arm" (45), whilst intra-dermal immunisation was given in the upper arm (35) or forearm (40) . In those studies assessing DTH response, intra-dermal KLH was administered to the volar aspect of the forearm (29), upper arm (13) or gluteal aspect of the leg (44) .
Older studies have used immunisation doses of KLH up to 5000µg (21) , although the range in the recent clinical studies reviewed was 8 µg to 1000 µg, with 100 µg being the most frequent dose.
Only one study reviewed was unable to detect a quantifiable antibody response post-immunisation (34), which was likely attributable to the immunosuppressed state of the study population. In the
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only published study to assess the effect of different doses of the same KLH formulation, Curtis et al (21) reported no significant difference in the kinetics or magnitude of the immune response amongst participants immunised with 10µg, 100µg or 5000µg of HMW KLH.
Safety profile
KLH has an excellent clinical safety profile, as noted by several authors (23, 29 (71%), IgE in 2 (14%) and IgA in 1 (7%) of the studies that measured antibodies.
[Insert Table 2 ]
Studies have also differed in how the KLH antibody titre was read and presented. For example, standard curves have been generated using sera with known concentrations of KLH antibody, and against these the concentration of anti-KLH antibodies in subjects' samples were interpolated (33,35,38). Other studies have compared the optical density (measure of colour change/light absorbance in wells) of sample sera at defined dilutions with the positive and negative control sera on the same plate which also allowed adjustment for inter-plate variation in absorbance readings (28,31,32). One study assayed KLH IgG and IgM at three dilutions (not specified) and calculated the average across dilutions for analyses (30).
Quantifying the cell-mediated immunity response
Many of the studies reviewed assessed aspects of cell-mediated immunity ex vivo following KLH Table 1 ).
There are conflicting data regarding the minimum sensitising and subsequent skin test dose required to induce a reliable DTH response. Grant et al (32) were unable to elicit a DTH response after administration of a 5µg intra-dermal skin test dose three weeks following immunisation with 125µg
HMW KLH administered intra-muscularly. Contrasting with this finding, a very early study found that the DTH response was independent of initial sensitising immunisation dose (i.e. 5000µg / 100µg / Accepted Article 1µg were equivalent) (21 Accepted Article
